The body weight, liver weight and liver to body weight ratio were not different among the NAFLD and G-CSF treatment groups (M+G, M+GL) (Supplementary Table 4) (Figure 4). The gene discussed is CSF3; the disease is metabolic dysfunction-associated steatotic liver disease.